Rimonabant (also known as SR141716; trade names Acomplia, Zimulti)[3] is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States.[1][2] Rimonabant is an inverse agonist for the cannabinoid receptor CB1 and was first-in-class for clinical development.[4][5]
^ abSam AH, Salem V, Ghatei MA (2011). "Rimonabant: From RIO to Ban". Journal of Obesity. 2011: 432607. doi:10.1155/2011/432607. PMC 3136184. PMID 21773005.
^ abMoreira FA, Crippa JA (June 2009). "The psychiatric side-effects of rimonabant". Revista Brasileira de Psiquiatria. 31 (2): 145–153. doi:10.1590/s1516-44462009000200012. PMID 19578688.
^"Rimonabant". AdisInsight. Retrieved 21 February 2017.
^Fong TM, Heymsfield SB (September 2009). "Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions". International Journal of Obesity. 33 (9): 947–955. doi:10.1038/ijo.2009.132. PMID 19597516.
^"European Approval Comes Early for Sanofi-Aventis' Acomplia". IHS. June 23, 2006.
Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug approved in Europe in 2006 but was withdrawn worldwide...
receptor antagonists. The first CBR inverse agonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and has been shown...
seen with an antagonist. An example is the cannabinoid inverse agonist rimonabant. A superagonist is a term used by some to identify a compound that is...
oxaloacetate supplements had no effect on lifespan in healthy laboratory mice. Rimonabant (Acomplia) is an anti-obesity drug initially approved for use in the European...
The antihypertensive effect of Spilanthol was blocked by CB1 antagonist Rimonabant and TRPV1 antagonist Capsazepine suggesting Spilanthol mediates some activity...
including flunarizine, mefloquine, and efavirenz. Another notable agent is rimonabant, a cannabinoid receptor antagonist marketed as an anti-obesity agent which...
drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to...
adverse cardiovascular risk profile. Similarly, the appetite suppressant rimonabant (a cannabinoid receptor antagonist) had to be withdrawn when it was linked...
depression, and thoughts of suicide in patients treated with the now-withdrawn rimonabant, another CB1 antagonist that was also under development by Sanofi-Aventis...
mianserin) -ant for various receptors antagonists (e.g. aticaprant and rimonabant) -arit for antiarthritic agents (e.g. lobenzarit) -ase for enzymes (e...
endocannabinoids bind to both receptor types. CB1 selective antagonists such as rimonabant are used for weight reduction and smoking cessation. A substantial number...
Global Information
